このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

有色人種の皮膚を持つ患者のにきび瘢痕治療のためのハイブリッド フラクショナル レーザーの有効性と忍容性

2026年9月29日 更新者:Montefiore Medical Center

The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative/ablative laser for acne scarring in skin of color.

調査の概要

詳細な説明

Acne is chronic inflammatory condition involving the pilosebaceous unit. One of the most common complications of acne is scarring, which occurs as a result of dermal damage during the healing process of active acne. Studies have shown that acne scarring can have a negative impact on an individual's quality of life and has been described as a risk factor for multiple psychiatric conditions including depression, anxiety, suicide, and poor self-esteem. Unfortunately, treatment of acne scarring, particularly those of the atrophic subtype, prove difficult to treat. A 2016 Cochrane review failed to provide sufficient evidence to support the first-line use of any intervention. Laser technology has been emerging as an effective, non-invasive treatment of acne scarring. Ablative lasers work by delivering energy to the dermal layer of the skin, resulting in thermal injury and stimulation of dermal cells to produce collagen, thus resolving the scar. More recently, fractional lasers, which create multiple tiny columns of thermal injury, have been introduced with the benefit of reduced downtime and adverse effects compared to ablative lasers. The fractional CO2 laser is widely used for the treatment of acne scarring, however its use is limited in patients of Fitzpatrick IV and V skin due to risk of hyperpigmentation among other adverse events. The erbium-YAG fractional laser serves as an alternative, and has shown to produce less thermal injury and thus be more well-tolerated with lower risk of adverse effects in patients. The hybrid fractional laser combines a 2940 nm wavelength with a 1470 wavelength and has an ablative component targeting the epidermis and a nonablative component targeting the dermis at the same spot. The investigators seek to investigate the Sciton Halo, hybrid fractional laser for its efficacy in treating acne scarring and tolerability in patients with a specific emphasis on those with Fitzpatrick IV and V skin.

研究の種類

介入

入学 (推定)

50

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • New York
      • Elmsford、New York、アメリカ、10523
        • 募集
        • 555 Taxter Road
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for acne scarring
  • Subject must voluntarily sign and date an IRB approved informed consent form
  • Subjects with diagnosis of acne scarring recorded over the past 6 months
  • Able to read, understand and voluntarily provide written informed consent.
  • Subject is determined to be healthy, non-smoker
  • Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.

Exclusion Criteria:

  • Subjects does not have the capacity to consent to the study
  • Subject underwent any acne scar treatments in the past 6 months prior to enrollment in the study
  • Subject has active papulopustular or cystic acne within the past 6 months
  • Any history of keloidal scarring
  • Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months
  • History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months
  • Subject has no health contraindications to receiving local lidocaine and epinephrine injections, including but not limited to any form of heart disease or arrhythmia, untreated or uncontrolled severe hypertension, uncontrolled hyperthyroidism, uncontrolled diabetes, pheochromocytoma, cocaine use
  • History or current use of the following prescription medications:

Immunosuppressive medications/biologics, 6 months prior to and during the study.

Accutane or other systemic retinoids within the past twelve months TCA, MAO, or beta-blockers

  • Smoking or vaping in the past 12 months
  • History of photosensitivity and/or connective tissue disease
  • History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders
  • History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism
  • History of ongoing pregnancy, active breastfeeding, cancer, and epilepsy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Hybrid Fractional laser - SOC

23 participants with fitzpatrick skin type IV-V will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.

Laser treatment

他の名前:
  • Scitonハイブリッドフラクショナルレーザー
  • ハイブリッドフラクショナルレーザー
  • シリアル番号: 88086862
実験的:Hybrid Fractional laser- Non- SOC

23 participants with Fitzpatrick skin type I-III will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.

Laser treatment

他の名前:
  • Scitonハイブリッドフラクショナルレーザー
  • ハイブリッドフラクショナルレーザー
  • シリアル番号: 88086862

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Acne Scar Severity
時間枠:Baseline to Month 9

Change in acne scarring severity from baseline to nine months will be assessed using the Global Scale for Acne Scar Severity (SCAR-S) scale. The SCAR-S is a validated scale used to assess the severity of acne scarring using a 6-point scale ranging from 0 ("Clear, no visible scars from acne") to 5 ("Very Severe; entire area with prominent atrophic or hypertrophic scars") such that higher scores are indicative of more severe scarring. Two independent blinded dermatologists will rate before and after treatment images using the SCAR-S scale. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 9
Change in Clinician Graded Global Assessment of Improvement Scale (GAIS) score
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Change in aesthetic success from baseline will be evaluated using the Clinician's Global Assessment of Improvement Scale (CGAIS). The CGAIS evaluates overall efficacy and cosmetic outcomes of the treatment. The CGAIS is based upon a 7-point scale ranging from -3 ("Greatly worsened") to +3 ("Greatly improved"), with 0 ("No change") as the midpoint. Two independent unbiased blinded dermatologists will conduct live/photographic assessments to evaluate patients at baseline, Month 2, Month 3, Month 4, Month 6, and Month 9. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Overall Patient Satisfaction
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Overall patient satisfaction will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in how their skin looks using a 7-point scale ranging from -3 ("Greatly decreased") to +3 ("Greatly increased"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of Acne Scarring
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of acne scarring will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in acne scarring in the area treated using a 7-point scale ranging from -3 ("Greatly decreased") to +3 ("Greatly increased"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of Skin Texture
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of skin texture will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in their skin texture using a 7-point scale ranging from -3 ("Greatly improved") to +3 ("Greatly worsened"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of Skin Pigmentation
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of skin pigmentation will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in their skin pigmentation using a 7-point scale ranging from -3 ("Greatly improved") to +3 ("Greatly worsened"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of General Skin Changes - Binary
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of general skin changes will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients "beyond texture, pigmentation, and overall acne scarring, did you notice any other changes in the area that was treated." Patients will select either "Yes" or "No." Binary responses will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of General Skin Changes - Categorical
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients who confirmed that they did notice changes in the "Patient Assessment of General Skin Changes - Binary" query on the PSQ will be asked to specify what those changes were from a menu of options. These options are "Pores are smaller," "Skin is less oily," "Skin is smoother," "Skin feels better," "Skin looks more radiant," "Face feels more youthful," and "Other." Patients will have the option of selecting more than one response. Responses will be categorically summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Satisfaction with Treatment
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient satisfaction with treatment will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients how they would characterize their satisfaction with the treatment using the following suite of options: "Very dissatisfied," "Dissatisfied," "Slightly dissatisfied," "Neither Satisfied or Dissatisfied," "Slightly satisfied," "Satisfied," or "Very Satisfied." Ordinal responses will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Recommend Treatment to Family and Friends
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they would recommend the treatment to friends and family members using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of recommendations to family/friends will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient adherence to skin care accommodations for laser treatment
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they are following skin care accommodations for laser treatment using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of adherence to skin care accommodations for laser treatment will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Daily mineral sunscreen use
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they are using daily mineral sunscreen of SPF30 or greater on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of usage will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Sun avoidance
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they are avoiding the sun on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of sun avoidance will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Treatment-related Side Effects
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

One of the safety variables will be treatment-related side effects. Patients will be asked whether they are experienced any of the following side effects following laser treatment: "Erythema," "Prolonged erythema," "Acne flare up," "Hypopigmentation," and "Hyperpigmentation." on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Patients can select any/all treatment-related side effects which they experienced. Responses will be categorically summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Pain Discomfort
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

One of the safety variables will be pain discomfort. Patients will be asked to quantify the degree of pain discomfort experienced following treatment using a pain scale item provided on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Patients will rate their pain discomfort on an 11-point Likert scale ranging from 0 ("No Pain") to 10 ("Worst Possible Pain"), such that higher scores are indicative of increased pain discomfort. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

その他の成果指標

結果測定
メジャーの説明
時間枠
Dermatology Quality of Life
時間枠:Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Dermatology quality of life will be assessed using the Dermatology Life Quality Index (DLQI). The DLQI is a standardized 10-item dermatology scale which determines how much impact a skin condition has had on life quality. Patients are asked to consider how much their skin problem has affected their life over the prior week when responding to each question. Questions are subjectively answered by patients using the following choices: "Very much" (= 3 points), "A lot" (= 2 points), "A little" (= 1 point), and "Not at all" or "Not relevant" (= 0 points). Scores are summarized for an overall possible range of 0-30, such that higher scores are indicative of greater dermatology-related life quality impairment. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Kseniya Kobets, MD、Montefiore Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年10月11日

一次修了 (推定)

2029年7月1日

研究の完了 (推定)

2029年7月1日

試験登録日

最初に提出

2022年4月18日

QC基準を満たした最初の提出物

2022年5月4日

最初の投稿 (実際)

2022年5月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

No individual participant data will not be available to researchers not part of the original research team. All patient data will be de-identified.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する